PO.ET09.02 · 实验与分子治疗

Epigenetic Modulators 2

21 张海报 20 张含资料时间 Apr 22 2026 9:00AM 区域 Section 12

7054 · PDF BET结构域在IDH1 R132H/p53突变/ATRX缺失星形细胞瘤恶性进展中的功能 BET domain functions in IDH1 R132H /p53 mut /ATRX loss astrocytoma malignancy Leyi Xie, Qingzhu Gao, Jayden Zhang, Lopez-BertoniHernando, John Laterra, Yunqing Li
7055 · PDF EZH1/2双重抑制剂HM97662联合DNA损伤剂对携带SMARCA4缺失的恶性肺癌的协同效应 Synergistic effects of HM97662 as an EZH1/2 dual inhibitor combined with DNA-damaging agents on malignant lung cancers harboring SMARCA4-deficiency Seung Hyun Jung, Jaeyul Choi, Aran Park, Seungheon Baek, Jooyun Byun, Young Gil Ahn
7056 · PDF Telomir-1：一种靶向衰老相关疾病和癌症的新型金属离子调节剂 Telomir-1: A novel metal ion modulator targeting aging-related disorders and cancer Itzchak Angel, Erez Aminov
7057 · PDF PCNA与HDAC抑制剂联合在皮肤T细胞淋巴瘤及其他癌症中的治疗潜力 Therapeutic potential of PCNA and HDAC inhibitor combinations in cutaneous T-cell lymphoma and other cancers Caroline M. Li, Robert G. Lingeman, Long Gu, Robert J. Hickey, Linda H. Malkas
7058 · PDF 高选择性HDAC6抑制剂：它们是免疫调节的答案吗？ Highly selective HDAC6 inhibitors: Are they the answer for immunomodulation? Silvia Rizzo, Edoardo Cellupica, Chiara Ripamonti, Grazia Rovelli, Barbara Vergani, Valeria Spadotto, Michela Bottani, Christian Steinkuhler, Gianluca Fossati
7060 · PDF 靶向KMT2C通过调控DREAM靶点在KMT2D缺失的DLBCL中诱导旁系同源物合成致死 Targeting KMT2C induces paralog synthetic lethality in KMT2D null DLBCL through DREAM targets regulation Hsiangyu Hu, Neeraj K. Aryal, Tim Nieuwenhuis, Daniel Barrell, Ultan McDermott, Laura B. Prickett, Ming Tang, Derek Oien, Laura Pasqualucci, Anas Younes, Lisa Drew, Omid Tavana
7061 7061 一种新型CBP/p300抑制剂在融合阳性横纹肌肉瘤中的机制理解 Mechanistic understanding of a novel CBP/p300 inhibitor in fusion-positive rhabdomyosarcoma Md Imdadul H. Khan, Matthew Chang, Yaw Asante, Maya Al-Haddad, Jordyn Kelly, Bhavatharini Udhayakumar, Carrietta Farma-Hai, Berkley Gryder
7062 · PDF EP102：METTL3的药理学抑制作为单药治疗有效，并通过DNA损伤和干性调节增强胰腺腺癌的放射治疗 EP102: Pharmacological inhibition of METTL3 is effective as a monotherapy and potentiates radiation therapy in pancreatic adenocarcinoma via DNA damage and stemness modulation Andrea Casazza, Nicolas Parmentier, Catherine Sorlet, Killian Oukoloff, Guillaume Dutheuil, Graeme L. Fraser
7063 · PDF p300溴结构域抑制剂通过诱导衰老抑制HPV阳性头颈部鳞状细胞癌的细胞增殖 p300 bromodomain inhibitors impair cell proliferation by inducing senescence in HPV positive head and neck squamous cell carcinoma Jessica Catarine Frutuoso do Nascimento, Wendi Quinn O'Neill, Quintin Pan
7064 · PDF 一类具有体内疗效的新型KAT6A/B抑制剂的研发 Development of a new class of KAT6A/B inhibitors with in vivo efficacy Antonius ter Laak, Roman Hillig, Steven Ferrara, Daniel Korr, Peter Staller, Naomi Barak, Philip Lienau, Simon Herbert, Amaury Fernandez, Roland Neuhaus, Matyas Gorjanacz, Vera Puetter, Volker Badock, Wilhelm Bone, Craig Strathdee, Franziska Siegel, Christoph Schatz, Nowak-Reppel Katrin, Olaf Doehr, Stefan Gradl, Ingo Hartung, Matthew Meyerson, Lea Bouche
7065 · PDF 使用RAS抑制剂联合AMG 193(一种MTA协同的PRMT5抑制剂)靶向MTAP缺失/KRAS突变癌症 Targeting MTAP-deleted/KRAS mutant cancers using RAS inhibitors in combination with AMG 193, an MTA-cooperative PRMT5 inhibitor Katherine Slemmons, Siyuan Liu, Chun Su, Raul Lazaro, Tao Osgood, Rati Verma, Brian Belmontes, Paul E. Hughes
7066 · PDF RG-7388、CM-272和SGI-1027的体内比较评估以确定表观遗传靶向作为治疗高危神经母细胞瘤有效策略 Comparative in vivo evaluation of RG-7388, CM-272, and SGI-1027 to determine epigenetic targeting as an effective strategy for treating high-risk neuroblastoma Umamaheswari Natarajan, Shyam S. Jaganathan, Appu Rathinavelu
7067 · PDF 通过联合DNA甲基转移酶(DNMT)抑制剂在癌细胞中产生协同细胞毒性 Synergistic cytotoxicity through combination of DNA methyltransferase (DNMT) inhibitors in cancer cells Angelo B. A. Laranjeira, Dat Nguyen, Michael Difilippantonio, Alice P. Chen, Sherry X. Yang, James H. Doroshow
7069 · PDF 共同靶向menin和LSD1可拆解致癌程序并在MLL重排急性髓系白血病中恢复分化 Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged acute myeloid leukemia Tulasigeri Totiger, Mina Tayari, Claudia Cabrera Pastrana, Florencio Munoz-Legarre, Anna Kingham, Helena Gomes Dos Santos, Felipe Beckedorff, Eduardo Bravo, Katarzyna Ciurko, Declan Foley, Efe Karaca, Daniel Bilbao, Claude-Henry Claude-Henry Volmar, Shaun P. Brothers, Ramin Shiekhattar, Justin Watts, Justin Taylor
7070 · PDF 丁酸盐调节口腔鳞状细胞癌的关键致癌通路:来自转录组分析的见解 Butyrate modulates key oncogenic pathways in oral squamous cell carcinoma: Insights from transcriptomic profiling Oscar A. Loperena Gonzalez, Ariana S. García- López, Liah M. Román-Calderón, Gabriel Borges Vélez, Esther Peterson Peguero, Josué Pérez Santiago
7071 · PDF CRISPRi筛选鉴定表观遗传脆弱性和ARID1A-PRC2合成致死轴使皮肤T细胞淋巴瘤对JAK/STAT和EZH2联合抑制敏感 CRISPRi screening identifies epigenetic vulnerabilities and an ARID1A-PRC2 synthetic-lethal axis sensitizing cutaneous T-cell lymphoma to combined JAK/STAT and EZH2 inhibition Yan-Jin Liu, Laura Pincus, Yu-Ru Chang, Frank McCormick, Weiyun Z. Ai
7073 · PDF 在急性白血病模型中靶向抑制PRC1可诱导显著的细胞生长和分化效应 Targeted inhibition of PRC1 in acute leukemia models induces prominent cell growth and differentiation effects Sydney Musser, Yiwu Yao, Se Ra Park, Miranda Simes, Hongzhi Miao, Alyssa Winkler, Trupta Purohit, Jolanta Grembecka, Tomasz Cierpicki
7074 · PDF PLX-61639是一种强效、口服生物利用度高的SMARCA2选择性单价直接降解剂，可增强标准治疗药物在SMARCA4突变型肿瘤模型中的疗效 PLX-61639, a potent and orally bioavailable SMARCA2-selective monovalent direct degrader, enhances efficacy of standard of care agents in SMARCA4 mutant tumor models Greg Parker, Geoffray Leriche, Aleksandar Jamborcic, Taylor Kampert, Linette Yang, Julia Toth, Kenneth Steadman, Jay Chung, Duc Tran, Luis Lopez, Farhana Barmare, Kyohei Hayashi, Gang Liu, Jianguo Ma, Alex Campos, Meg McCarrick, Kevin Freeman-Cook, Peggy Thompson
7075 · PDF FHT-171的临床前特征鉴定：一种针对CBP依赖性实体瘤中CREB结合蛋白（CBP）的首创降解剂 Preclinical characterization of FHT-171, a first-in-class degrader targeting CREB-binding protein (CBP) in CBP-dependent solid tumors Darshan Sappal, Molly M. Wilson, Laura La Bonte, Meiyun Lin, Breanna Bullock, Shawn Schiller
7076 · PDF 发现一种高效、选择性的KAT6A降解剂ATH-002，在临床前研究中表现出强大的抗肿瘤活性且血液毒性风险低 Discovery of a highly potent and selective KAT6A degrader ATH-002 that demonstrates robust anti-tumor activity with a low risk of hematotoxicity in preclinical studies Hanyu Wang, Lei Jiang, Youxi Chen, Baoying Chen, Yuyao Zhang, Nianfeng Huang, Fan Yang, Feng Zhou
7077 · PDF ISM1745：一种用于治疗MTAP缺失型癌症的MTA协同性PRMT5抑制剂 ISM1745, an MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer Yilin Yang, Zhongying Cao, Meng Zhang, Xiaoyu Ding, Hongfu Lu, Qingchuan Zhao, Xiaoxia Lin, Jiaojiao Yu, David Gennert, Suguna Rachakonda, Xiao Ding, Xin Cai, Man Zhang, Feng Ren, Alex Zhavoronkov

在会议检索中浏览本分会场